Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.

At StockStory, we look beyond the headlines with our independent analysis to determine whether these bullish calls are justified. Keeping that in mind, here are three stocks where Wall Street may be overlooking some important risks and some alternatives with better fundamentals.

NN (NNBR)

Consensus Price Target: $5.50 (247% implied return)

Formerly known as Nuturn, NN (NASDAQ: NNBR) provides metal components, bearings, and plastic and rubber components to the automotive, aerospace, medical, and industrial sectors.

Why Do We Think NNBR Will Underperform?

1. Flat sales over the last five years suggest it must find different ways to grow during this cycle
2. Cash-burning history makes us doubt the long-term viability of its business model
3. Waning returns on capital from an already weak starting point displays the inefficacy of management’s past and current investment decisions

NN is trading at $1.59 per share, or 29.4x forward P/E. To fully understand why you should be careful with NNBR, check out our full research report (it’s free).

GE HealthCare (GEHC)

Consensus Price Target: $91.74 (24.6% implied return)

Spun off from industrial giant General Electric in 2023 after over a century as its healthcare division, GE HealthCare (NASDAQ: GEHC) provides medical imaging equipment, patient monitoring systems, diagnostic pharmaceuticals, and AI-enabled healthcare solutions to hospitals and clinics worldwide.

Why Are We Wary of GEHC?

1. Scale is a double-edged sword because it limits the company’s growth potential compared to its smaller competitors, as reflected in its below-average annual revenue increases of 2.7% for the last two years
2. Absence of organic revenue growth over the past two years suggests it may have to lean into acquisitions to drive its expansion

GE HealthCare’s stock price of $73.60 implies a valuation ratio of 14.5x forward P/E. Dive into our free research report to see why there are better opportunities than GEHC.

Collegium Pharmaceutical (COLL)

Consensus Price Target: $54.17 (52% implied return)

Pioneering abuse-deterrent technology in a field plagued by addiction concerns, Collegium Pharmaceutical (NASDAQ: COLL) develops and markets specialty medications for treating moderate to severe pain, including abuse-deterrent opioid formulations.

Why Are We Cautious About COLL?

1. Smaller revenue base of $780.6 million means it hasn’t achieved the economies of scale that some industry juggernauts enjoy
2. Day-to-day expenses have swelled relative to revenue over the last two years as its adjusted operating margin fell by 4.8 percentage points
3. Diminishing returns on capital suggest its earlier profit pools are drying up

At $35.63 per share, Collegium Pharmaceutical trades at 4.8x forward P/E. Read our free research report to see why you should think twice about including COLL in your portfolio.

Stocks We Like More

ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.

Find out which 5 stocks it's flagging for this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.